High Lp(a) Polygenic Risk Score

About one in five adults quietly carries an inherited tendency to make a lot of lipoprotein(a), a sticky cholesterol particle that drives heart attacks and strokes regardless of how clean a lifestyle is. Most people will never know because it does not show up on a routine cholesterol panel.

A high Lp(a) (lipoprotein little a) polygenic risk score reads dozens of inherited DNA markers and combines them into a single number that estimates how much lipoprotein(a) your body is genetically programmed to make for life. It answers a question a standard lipid panel cannot: whether your biology is quietly tilting your arteries toward disease.

What This Score Actually Measures

Lipoprotein(a) levels are mostly inherited, with roughly 70 to 90 percent of the variation between people written into DNA. A widely used polygenic risk score, a single number built from many small genetic variants (PRS), combines 43 independent variants at the LPA gene, the main gene that controls lipoprotein(a) production. In people of European ancestry, this score explains close to 60 percent of the differences in lipoprotein(a) levels between individuals.

Because the underlying particle is stable across decades, a single DNA-based reading captures something a one-time blood test can hint at but never fully prove: your lifelong exposure to this specific cardiovascular risk.

Heart Attack and Plaque Risk

When researchers scanned nearly 23,000 veterans who had coronary imaging, a genetically predicted high level of lipoprotein(a) tracked with more obstructive plaque in the coronary arteries. The link held even after accounting for measured LDL (low-density lipoprotein) cholesterol and a genetic score for LDL. In plain terms, your inherited lipoprotein(a) tendency adds heart attack risk on top of your cholesterol number, not because of it.

In the UK Biobank, both directly measured lipoprotein(a) and the 43-variant LPA score independently predicted future atherosclerotic events. The score's link to events was largely explained by the elevated lipoprotein(a) it produces, confirming that the DNA reading is acting through the same biology you would see in a direct blood test.

A separate analysis of more than 76,000 people combined the LPA score with the KIV-2 repeat, a structural piece of the gene that strongly shapes lipoprotein(a) levels. People in the high combined genetic risk group had substantially higher risk of coronary artery disease (CAD) than those in the low group, and many had heart attacks despite having none of the traditional risk factors like high LDL or high blood pressure.

Inherited High Cholesterol and Unexplained Cases

Familial hypercholesterolemia (FH), an inherited form of very high cholesterol, is sometimes diagnosed clinically even when no single known mutation can be found. In a sequencing study within the 100,000 Genomes Project, a high lipoprotein(a) polygenic score showed up in about 18.5 percent of these unexplained cases. If you have been told you have FH but no clear gene was identified, an inherited lipoprotein(a) signal can be quietly driving the picture.

Ancestry and Score Accuracy

Most current Lp(a) polygenic scores were built from European populations and work best there. In people of African ancestry, the same score still associated with measured lipoprotein(a), but the link was weaker. Score performance is not uniform across all ancestries, and researchers are actively working on more inclusive versions. If you are not of European descent, the score still carries information, but it deserves to be interpreted alongside a direct blood measurement of lipoprotein(a).

Reading This Score Honestly

Standardized clinical cutpoints for this score are not yet locked down by guideline bodies, which is why it sits in the emerging research-to-clinic gray zone. The signal is real, but its value comes from how it changes what you do next, not from a single threshold.

When added to QRISK3, a widely used cardiovascular risk calculator, either a measured lipoprotein(a) reading or the LPA polygenic score improved discrimination only modestly, with the area under the curve moving from 0.640 to 0.642 (where 0.5 is a coin flip and 1.0 is perfect). The score is not a stand-alone verdict. It is a piece of evidence that, combined with a direct lipoprotein(a) blood test and your other lipid numbers, sharpens an otherwise blurry picture of your long-term heart risk.

Why One Reading Is the Reading

Your DNA does not change. Unlike cholesterol or inflammation markers, this score does not bounce around with diet, illness, or time of day, and you do not need to retest it serially. What changes is the interpretation: as scores are refined, especially across ancestries, and as lipoprotein(a)-lowering drugs move closer to approval, the same result you have today will be read with more nuance in five years. Getting your baseline now means you will have it in hand when those tools arrive.

Even though the DNA reading is fixed, you should pair it with at least one direct lipoprotein(a) blood measurement, then track your other lipids, inflammation markers, and blood pressure at least annually if you are actively managing cardiovascular risk.

When Results Can Be Misleading

• Ancestry mismatch: the score was developed mainly in people of European descent and predicts lipoprotein(a) levels less reliably in African and other ancestries.
• Missing structural variation: the score reads single-letter DNA variants, but a separate structural region of the gene called the KIV-2 repeat also shapes lipoprotein(a) levels and is not always captured.
• Score is not a diagnosis: a high score predicts a high lifelong tendency, not your level on any given day. A direct blood test confirms what your body is actually producing right now.
• Modest standalone discrimination: adding the score alone to standard risk calculators only nudges accuracy. It earns its keep as part of a fuller workup, not on its own.

What to Do With a High Result

A high score should prompt action, not panic. First, confirm with a direct lipoprotein(a) blood test to see your actual particle concentration. Pair it with an ApoB (apolipoprotein B) measurement, which counts every atherogenic particle in your blood, and a high-sensitivity CRP (C-reactive protein) for vascular inflammation. If your LDL or ApoB is also elevated, the combination dramatically raises your lifetime cardiovascular risk and deserves aggressive management with a preventive cardiologist or lipidologist.

If you have first-degree relatives, especially anyone with early heart attack, stroke, or unexplained high cholesterol, share the result. Lipoprotein(a) tendency runs in families, and cascade screening relatives can prevent events upstream. A high score is also a reason to consider earlier coronary calcium scoring or advanced imaging if you fall in an intermediate clinical risk band.